Jenna Reps, ScD

Janssen Research and Development, LLC

Poster(s):

• (212) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of methylphenidate and potential signal for obsessive-compulsive disorders
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (292) Prediction of Hemolytic Disease of the Fetus and Newborn in neonates from alloimmunized pregnancies
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (299) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of paliperidone, risperidone, and low-energy fracture
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (CSPOT23) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of infliximab and alternative autoimmune conditions
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST